Outset Medical, Inc. (OM) Spending and interest coverage
- R&D / revenue · 12 months: Value 18.25%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 12.98%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -4.81×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 18.25% | Research and development expense / revenue. Period ending 2026-06-30. $21.50M ÷ $117.80M × 100 ≈ 18.25% |
| Stock-based compensation / revenue · 12 months | 12.98% | Share-based compensation / revenue. Period ending 2026-06-30. $15.29M ÷ $117.80M × 100 ≈ 12.98% |
| Interest coverage · 12 months | -4.81× | Operating income ÷ reported interest expense. $-66.04M ÷ $13.73M ≈ -4.81× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 21.50M USD | Research and Development Expense |
| Revenue | 117.80M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 15.29M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -66.04M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 13.73M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $21.50M | $117.80M | $15.29M | $-66.04M | $13.73M | 18.25% | 12.98% | -4.81× | Reported |
| 2026-03-31 | $21.34M | $117.59M | $16.09M | $-67.23M | $13.76M | 18.15% | 13.69% | -4.89× | Reported |
| 2025-12-31 | $21.23M | $119.48M | $15.62M | $-66.71M | $13.95M | 17.77% | 13.07% | -4.78× | Reported |
| 2025-09-30 | $24.07M | $120.07M | $16.50M | $-70.94M | $16.34M | 20.05% | 13.74% | -4.34× | Reported |
| 2025-06-30 | $26.83M | $119.30M | $17.81M | $-78.96M | $18.93M | 22.49% | 14.92% | -4.17× | Reported |
| 2025-03-31 | $31.28M | $115.27M | $24.13M | $-92.86M | $21.46M | 27.13% | 20.93% | -4.33× | Reported |
| 2024-12-31 | $38.40M | $113.69M | $29.36M | $-113.38M | $23.87M | 33.77% | 25.82% | -4.75× | Reported |
| 2024-09-30 | $43.04M | $114.73M | $33.51M | $-128.87M | $21.46M | 37.51% | 29.21% | -6.00× | Reported |
| 2024-06-30 | $50.98M | $116.42M | $38.01M | $-150.48M | $18.61M | 43.79% | 32.65% | -8.09× | Reported |
| 2024-03-31 | $56.15M | $125.08M | $38.30M | $-163.20M | $15.70M | 44.89% | 30.62% | -10.39× | Reported |
| 2023-12-31 | $57.31M | $130.38M | $38.63M | $-169.77M | $12.68M | 43.96% | 29.63% | -13.39× | Reported |
| 2023-09-30 | $56.22M | $131.88M | $36.89M | $-172.24M | $11.35M | 42.63% | 27.97% | -15.17× | Reported |
| 2023-06-30 | $53.20M | $129.28M | $33.43M | $-167.79M | $8.71M | 41.15% | 25.86% | -19.27× | Reported |
| 2023-03-31 | $51.82M | $118.29M | $30.73M | $-168.03M | $6.09M | 43.80% | 25.98% | -27.61× | Reported |
| 2022-12-31 | $48.85M | $115.38M | $27.20M | $-161.02M | $3.57M | 42.34% | 23.58% | -45.15× | Reported |
| 2022-09-30 | $48.82M | $111.52M | $24.64M | $-161.99M | $1.90M | 43.78% | 22.10% | -85.22× | Reported |
| 2022-06-30 | $45.49M | $110.08M | $20.08M | $-151.13M | $1.76M | 41.33% | 18.24% | -85.63× | Reported |
| 2022-03-31 | $40.00M | $110.24M | $16.60M | $-137.32M | $1.72M | 36.29% | 15.06% | -80.07× | Reported |
| 2021-12-31 | $36.74M | $102.60M | $17.45M | $-130.52M | $1.72M | 35.81% | 17.00% | -76.10× | Reported |
| 2021-09-30 | $33.12M | $91.70M | $18.92M | $-121.33M | $1.71M | 36.11% | 20.63% | -70.79× | Reported |
| 2021-06-30 | $32.56M | $79.14M | $29.96M | $-131.93M | $1.71M | 41.15% | 37.87% | -77.11× | Reported |
| 2021-03-31 | $30.58M | $65.66M | $26.71M | $-126.93M | $2.31M | 46.58% | 40.68% | -54.90× | Reported |
| 2020-12-31 | $28.85M | $49.94M | $21.44M | $-117.47M | $2.89M | 57.78% | 42.93% | -40.63× | Reported |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $28.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $19.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $23.33M | $15.08M | $883.00K | $-70.31M | $4.26M | 154.71% | 5.86% | -16.52× | Reported |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $22.92M | $2.01M | $788.00K | $-46.56M | $4.64M | 1141.80% | 39.26% | -10.04× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| IRIDEX CORP (IRIX) | United States | $0.011B | |
| ENDRA Life Sciences Inc. (NDRA) | United States | $0.009B | |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Nuwellis, Inc. (NUWE) | United States | $0.003B |